반응식
CO[C:3](=[O:37])[N:4]=[C:5](SC)[C:6]([C:20]1[CH:25]=[CH:24][C:23]([O:26][CH2:27][C:28](=[O:31])[NH:29][CH3:30])=[C:22]([O:32][CH2:33][CH3:34])[CH:21]=1)=[N:7][C:8]1[CH:13]=[CH:12][C:11]([C:14]2[N:18]=C(C)O[N:15]=2)=[CH:10][CH:9]=1.[CH3:38][O:39][C:40]1[C:41]([NH:46][NH2:47])=[N:42][CH:43]=[CH:44][CH:45]=1>>[C:33]([OH:39])(=[O:32])[CH3:34].[C:14]([C:11]1[CH:12]=[CH:13][C:8]([NH:7][CH:6]([C:5]2[NH:4][C:3](=[O:37])[N:46]([C:41]3[C:40]([O:39][CH3:38])=[CH:45][CH:44]=[CH:43][N:42]=3)[N:47]=2)[C:20]2[CH:25]=[CH:24][C:23]([O:26][CH2:27][C:28]([NH:29][CH3:30])=[O:31])=[C:22]([O:32][CH2:33][CH3:34])[CH:21]=2)=[CH:9][CH:10]=1)(=[NH:18])[NH2:15]참가 물질
3
반응물 2
생성물 1
실험 절차
The same procedure was carried out as in Examples (21i)-(21j), except that {2-(3-ethoxy-4-methylcarbamoylmethoxyphenyl)-2-[4-(5-methyl-[1,2,4]oxadiazol-3-yl)phenylimino]-1-methylsulfanylethylidene}carbamic acid methyl ester was used instead of the {2-(8-methoxy-4H-benzo[1,3]dioxin-6-yl)-2-[4-(5-methyl-[1,2,4]oxadiazol-3-yl)-phenylimino]-1-methylsulfanylethylidene}carbamic acid methyl ester in Example (21i), and (3-methoxy-pyridin-2-yl)hydrazine was used instead of 2-hydrazinopyrimidine in Example (21i), to give the title compound.
출처 및 근거
- ORD 기록
- ord-075e8bc0f24f46259bdc8e189530002e
- 출처 데이터셋
- uspto-grants-2011_04
- 특허 번호
- US07928228B2
연결된 노트
불러오는 중…